2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow HYQVIA: new trials by email Literature Review of HYQVIA trials Research Report on HYQVIA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases TAK-881, HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Takeda | 65 | 2023-10-24 | 2026-09-30 |
| Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) HyQvia, Subcuvia - Multifocal Motor Neuropathy | Phase 2 | Completed | Johannes Jakobsen | 18 | 2016-06-01 | 2018-05-17 |
Primary Immunodeficiency Diseases (1)
Johannes Jakobsen (1) · Takeda (1)
Denmark (2) · Czechia (1) · Germany (1) · Netherlands (1) · Poland (1) · Slovakia (1) · Spain (1) · United States (1)